Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Top Cited Papers
- 9 December 2000
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 19 (53) , 6115-6121
- https://doi.org/10.1038/sj.onc.1203972
Abstract
This past decade has witnessed the remarkable advances in the understanding of the role of the erbB2 gene in cancers and the stunning progress in developing targeted therapies for erbB2-overexpressing cancers. Activation of the ErbB2 receptor signaling pathways can enhance various metastasis-associated properties that lead to an increase of cancer metastasis. Additionally, ErbB2 overexpression confers therapeutic resistance via receptor-mediated antiapoptotic signals. To limit these disastrous effects of the overexpressed ErbB2, various ErbB2-blocking strategies have been developed in the laboratories and several have been tested in clinical trials or approved as therapies for ErbB2 overexpressing cancers. In this article, we will discuss the detrimental effects of the erbB2 gene in cancers, with a focus on breast cancer. We will also outline ErbB2-targeting strategies as potential therapies for ErbB2-overexpressing cancers. Progress in understanding the molecular biology of ErbB2 and in molecular-based treatment of ErbB2-overexpressing tumors will bring great benefits to cancer patients.Keywords
This publication has 61 references indexed in Scilit:
- DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic miceGene Therapy, 2000
- E1A Sensitizes Cells to Tumor Necrosis Factor-induced Apoptosis through Inhibition of IκB Kinases and Nuclear Factor κB ActivitiesJournal of Biological Chemistry, 1999
- Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivoOncogene, 1998
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2Gene Therapy, 1997
- Evidence Supporting a Signal Transduction Pathway Leading to the Radiation-Resistant Phenotype in Human Tumor CellsBiochemical and Biophysical Research Communications, 1997
- Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinicJournal of Clinical Immunology, 1991
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985